Français
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
neurodegenerative diseases/protease
Le lien est enregistré dans le presse-papiers
Page 1 de 101 résultats
Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Alzheimer's disease (AD) is the most common form of both senile and presenile dementia in the world and is recognized clinically as relentlessly progressive dementia that presents with increasing loss of memory, intellectual function and disturbances in speech (Merritt,
Methods of treating neurodegenerative disorders using protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to peptidyl compounds useful for a variety of physiological end-use applications. More specifically, di- and tripeptide analogs that are useful in the treatment of neurodegenerative disease states and in the treatment of the degeneration of the neuronal
Methods of treating neurodegenerative disorders using protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to peptidyl compounds useful for a variety of physiological end-use applications. More specifically, peptide and amino acid analogs that are protease inhibitors are provided. These inhibitors are useful in the treatment of certain diseases, including
Substituted 5-membered n-heterocyclic compounds and their uses for treating or preventing neurodegenerative diseases
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
This application is a PCT application, PCT/CN02/00870, which was filed on Dec. 5, 2002, and claims the priority date of Dec. 6, 2001 in P. R. China.
FIELD OF THE INVENTION
This invention relates to substituted 5-membered N-Herterocyclic neurotrophic compounds, their preparation methods, compositions
tPA mutant in the treatment of acute brain injury and neurodegenerative disorders
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
REFERENCE TO CO-PENDING APPLICATIONS
Priority is claimed as a 371 of international of PCT/IL2009/000300, filed on Mar. 16, 2009, which claims priority to Israeli patent application number 190184 filed on Mar. 16, 2008.
FIELD OF THE INVENTION
The invention relates to compositions and methods in the
Aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
Aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
Tripeptide epoxy ketone protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
1. Field of the Invention
This disclosure relates to tripeptide epoxy ketone protease inhibitors including methods of making and using the same.
2. Description of Related Technology
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway
Tripeptide epoxy ketone protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
BACKGROUND OF THE INVENTION
Field of the Invention
This disclosure relates to tripeptide epoxy ketone protease inhibitors including methods of making and using the same.
Description of Related Technology
In eukaryotes, protein degradation is predominately mediated through the ubiquitin pathway in
Aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
Aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
Heterocyclic aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
Heterocyclic aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
Heterocyclic aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to heterocyclic aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human
Heterocyclic aspartyl protease inhibitors
Seuls les utilisateurs enregistrés peuvent traduire des articles
Se connecter S'inscrire
FIELD OF THE INVENTION
This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as inhibitors of the Human Immunodeficiency Virus,
La base de données d'herbes médicinales la plus complète soutenue par la science
- Fonctionne en 55 langues
- Cures à base de plantes soutenues par la science
- Reconnaissance des herbes par image
- Carte GPS interactive - étiquetez les herbes sur place (à venir)
- Lisez les publications scientifiques liées à votre recherche
- Rechercher les herbes médicinales par leurs effets
- Organisez vos intérêts et restez à jour avec les nouvelles recherches, essais cliniques et brevets
Tapez un symptôme ou une maladie et lisez des informations sur les herbes qui pourraient aider, tapez une herbe et voyez les maladies et symptômes contre lesquels elle est utilisée.
* Toutes les informations sont basées sur des recherches scientifiques publiées
